Anaphylactoid reaction during an infusion of recombinant tissue-type plasminogen activator for acute myocardial infarction.
Potentially life-threatening immediate hypersensitivity reactions are extremely rare among patients treated with thrombolytic agents for suspected acute myocardial infarction. A patient who developed a severe reaction during an infusion of recombinant tissue-type plasminogen activator is described. Potential causal mechanisms for the reaction could be related either to nonmedicinal additives or complement activation. Implications for treatment in the setting of acute myocardial infarction are discussed.
Department of Medicine, McMaster University, Hamilton, Ontario.
D
D
Massel
J B
JB
Gill
J A
JA
Cairns
D000368:Aged; D000707:Anaphylaxis / Q000209:etiology*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy*; D011994:Recombinant Proteins; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects* / Q000627:therapeutic use
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator